BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24109526)

  • 21. Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center.
    Gupta R; Yadav S; Parashar Y; Rahman K; Singh MK; Chandra D; Gupta A; Nityanand S
    Int J Lab Hematol; 2020 Feb; 42(1):37-45. PubMed ID: 31725954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
    Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gain of multiple copies of the CBFB gene: a new genetic aberration in a case of granulocytic sarcoma.
    Mallo M; Espinet B; Salido M; Ferrer A; Pedro C; Besses C; Pérez-Vila E; Serrano S; Florensa L; Solé F
    Cancer Genet Cytogenet; 2007 Nov; 179(1):62-5. PubMed ID: 17981216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.
    Gourdin TS; Zou Y; Ning Y; Emadi A; Duong VH; Tidwell ML; Chen C; Rassool FV; Baer MR
    Cancer Genet; 2014; 207(10-12):467-73. PubMed ID: 25441683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
    Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
    Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F
    Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns.
    Guan W; Zhou L; Li Y; Yang E; Liu Y; Lv N; Fu L; Ding Y; Wang N; Fang N; Liu Q; Wang B; Li F; Zhang J; Wang M; Wang L; Jing Y; Li Y; Yu L
    Exp Hematol Oncol; 2021 Apr; 10(1):27. PubMed ID: 33836835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia.
    Tallman MS; Hakimian D; Shaw JM; Lissner GS; Russell EJ; Variakojis D
    J Clin Oncol; 1993 Apr; 11(4):690-7. PubMed ID: 8478662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Moraleda PP; Gerbing RB; Raimondi SC; Hirsch BA; Ravindranath Y; Lange B; Woods WG; Gamis AS; Meshinchi S
    Br J Haematol; 2014 Jul; 166(2):254-259. PubMed ID: 24661089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solitary preleukemic granulocytic sarcoma as a cause of small bowel obstruction.
    Jung SH; Kim HC; Yu CS; Kim JC
    Gut Liver; 2007 Jun; 1(1):82-6. PubMed ID: 20485664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
    Kansal R
    Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical patterns in the differential diagnosis of rhinopharyngeal granulocytic sarcoma.
    Cantone E; Cavaliere M; Di Lullo AM; Guadagno E; Iengo M
    Oncol Lett; 2016 Oct; 12(4):2777-2781. PubMed ID: 27698857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups.
    Mały E; Przyborsk M; Nowak T; Nowak J; Januszkiewicz D
    Postepy Hig Med Dosw (Online); 2010 Oct; 64():466-70. PubMed ID: 20966504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azacytidine in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia Presenting with Pneumonia: A Case Series.
    Kurmi SR; Dayama A; Bhargava R
    Indian J Hematol Blood Transfus; 2020 Apr; 36(2):377-380. PubMed ID: 32425393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RUNX1 cooperates with FLT3-ITD to induce leukemia.
    Behrens K; Maul K; Tekin N; Kriebitzsch N; Indenbirken D; Prassolov V; Müller U; Serve H; Cammenga J; Stocking C
    J Exp Med; 2017 Mar; 214(3):737-752. PubMed ID: 28213513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.